A comparative study of adaptive dose-finding designs for phase I oncology trials of combination therapies

Stat Med. 2015 Oct 30;34(24):3194-213. doi: 10.1002/sim.6533. Epub 2015 May 13.

Abstract

Little is known about the relative performance of competing model-based dose-finding methods for combination phase I trials. In this study, we focused on five model-based dose-finding methods that have been recently developed. We compared the recommendation rates for true maximum-tolerated dose combinations (MTDCs) and over-dose combinations among these methods under 16 scenarios for 3 × 3, 4 × 4, 2 × 4, and 3 × 5 dose combination matrices. We found that performance of the model-based dose-finding methods varied depending on (1) whether the dose combination matrix is square or not; (2) whether the true MTDCs exist within the same group along the diagonals of the dose combination matrix; and (3) the number of true MTDCs. We discuss the details of the operating characteristics and the advantages and disadvantages of the five methods compared.

Keywords: combination of two agents; comparative study; dose-finding method; oncology; phase I trial.

Publication types

  • Comparative Study
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Algorithms
  • Antineoplastic Combined Chemotherapy Protocols / pharmacology*
  • Bayes Theorem
  • Clinical Trials, Phase I as Topic / methods*
  • Computer Simulation
  • Humans
  • Likelihood Functions
  • Logistic Models
  • Maximum Tolerated Dose*
  • Neoplasms / drug therapy*